US 11,718,624 B2
Solid state forms of substituted pyrazolopyrimidines and uses thereof
Hanlan Liu, Lexington, MA (US); Jeremy Clinton Wilt, Needham, MA (US); Friedrich Blatter, Reinach (CH); and Giuseppe Lapadula, Basel (CH)
Assigned to KSQ Therapeutics, Inc., Lexington, MA (US)
Filed by KSQ Therapeutics, Inc., Lexington, MA (US)
Filed on Oct. 28, 2021, as Appl. No. 17/512,802.
Claims priority of provisional application 63/107,765, filed on Oct. 30, 2020.
Prior Publication US 2022/0162213 A1, May 26, 2022
Int. Cl. C07D 487/04 (2006.01); A61P 35/00 (2006.01)
CPC C07D 487/04 (2013.01) [A61P 35/00 (2018.01); C07B 2200/13 (2013.01)] 27 Claims
 
1. A solid state form of 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-(4-(1-isopropyl-4-(trifluoromethyl)-1H-imidazol-2-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidine of Formula (II):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.